Loading
A166 is an experimental antibody-drug conjugate from Sichuan Kelun-Biotech Biopharmaceutical in phase 3 trials for HER2-positive breast cancer, aimed at HER2.
A166 is an antibody-drug conjugate developed by Sichuan Kelun-Biotech Biopharmaceutical. Its target is HER2 (the sponsor names HER2). The sponsor states: A166 is a HER2-targeted antibody-drug conjugate with a microtubule inhibitor payload, administered intravenously at 4.8 mg/kg every three weeks (Q3W) to HER2-positive breast cancer patients. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06968585 (A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy), in HER2-positive breast cancer. The largest, NCT06968585, plans to enrol 365 participants (actual) with primary completion expected 2026-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A166 is a HER2-targeted antibody-drug conjugate with a microtubule inhibitor payload, administered intravenously at 4.8 mg/kg every three weeks (Q3W) to HER2-positive breast cancer patients. Connects to HER2.
1.A166's antibody arm binds HER2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"A166" OR ABSTRACT:"A166") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about A166, not a curated reading list.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares HER2, HER2-positive breast cancer and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.